CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,230,167 | +20072.0% | 2,429,924 | +11697.5% | 0.11% | +10500.0% |
| Q1 2023 | $179,606 | -82.6% | 20,597 | -94.1% | 0.00% | -75.0% |
| Q2 2022 | $1,033,000 | -55.1% | 350,000 | -48.6% | 0.00% | -55.6% |
| Q4 2021 | $2,303,000 | +14.5% | 681,401 | +18.2% | 0.01% | -30.8% |
| Q2 2020 | $2,012,000 | -87.6% | 576,638 | -81.8% | 0.01% | -86.9% |
| Q3 2019 | $16,182,000 | -44.9% | 3,160,600 | -22.9% | 0.10% | -35.3% |
| Q2 2019 | $29,346,000 | +1597.3% | 4,098,630 | +1765.4% | 0.15% | +1812.5% |
| Q4 2018 | $1,729,000 | +110.3% | 219,715 | +196.1% | 0.01% | +166.7% |
| Q3 2018 | $822,000 | -27.8% | 74,197 | -91.2% | 0.00% | -66.7% |
| Q1 2016 | $1,139,000 | -34.9% | 843,800 | -18.5% | 0.01% | -35.7% |
| Q4 2015 | $1,750,000 | -12.8% | 1,035,288 | 0.0% | 0.01% | -12.5% |
| Q3 2015 | $2,008,000 | +27.6% | 1,035,288 | +76.9% | 0.02% | +45.5% |
| Q2 2015 | $1,574,000 | -61.1% | 585,288 | 0.0% | 0.01% | -60.7% |
| Q1 2015 | $4,050,000 | -27.9% | 585,288 | +2.5% | 0.03% | -28.2% |
| Q4 2014 | $5,614,000 | – | 571,088 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |